Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Nov. 14, 2024—Mainz Biomed, a Germany-based molecular genetics diagnostic company specializing in cancer diagnostics, announced a collaborative agreement with Thermo Fisher Scientific, through its subsidiary Life Technologies Corp., in which the companies will jointly develop and potentially commercialize Mainz Biomed’s next-generation colorectal cancer screening product.
Nov. 13, 2024—Healthbit announced it will launch its LabOS (laboratory operating system) at the Association for Molecular Pathology annual meeting in Vancouver, British Columbia, Nov. 19–23.
Nov. 11, 2024—Hardy Diagnostics announced it has entered into an exclusive partnership with Swedish-based company Gradientech to distribute Gradientech’s QuickMIC system in the Unites States and Canada.
Nov. 5, 2024—Tempus AI announced it has entered into an agreement to acquire Ambry Genetics.
Nov. 4, 2024—Qiagen announced that the FDA has cleared the QIAstat-Dx Meningitis/Encephalitis panel for clinical use.
Oct. 24, 2024—Pillar Biosciences has announced it has been granted a unique CPT proprietary laboratory analyses code 0523U from the American Medical Association for its FDA-approved OncoReveal CDx pan-cancer solid tumor in vitro diagnostic NGS kit.
Oct. 22, 2024—The FDA has approved zolbetuximab-clzb (Vyloy, Astellas Pharma), a claudin 18.2-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.
Oct. 18, 2024—Qiagen published a white paper, titled “NIH Study Finds HGMD Professional Demonstrates a 126% Higher Precision Score than AI-derived Databases,” that discusses expert curation tools that help identify relevant literature for variant classification and the findings of a study conducted by investigators at the National Human Genome Research Institute.
Oct. 17, 2024—Bio-Rad Laboratories has launched its External Quality Assurance Services specialty immunoassay program.
Oct. 16, 2024—Pillar Biosciences announced an expansion of its existing partnership with Illumina in which a broader portfolio of its OncoReveal NGS panels will be offered directly through Illumina.
